Singapore markets open in 3 hours 51 minutes

Straits Times Index
3,343.35
+11.65(+0.35%)
S&P 500
5,482.87
+4.97(+0.09%)
Dow
39,164.06
+36.26(+0.09%)
Nasdaq
17,858.68
+53.53(+0.30%)
Bitcoin USD
61,420.45
+419.19(+0.69%)
CMC Crypto 200
1,281.85
+15.70(+1.24%)

RPTX240719P00005000

. Currency in USD

Add to watchlist

(-)

Loading interactive chart…

Business Wire
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
CAMBRIDGE, Mass. & MONTREAL, June 26, 2024--Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI
Business Wire
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial
CAMBRIDGE, Mass. & MONTREAL, June 10, 2024--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of the TRESR clinical trial.
Zacks
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag
Repare (RPTX) rises 14% as the FDA grants Fast Track designation to its investigational lunresertib/camonsertib combo to treat adult ovarian cancer patients in the United States.